ADMA Biologics Inc vs iShares Core MSCI EAFE ETF — how do they compare? ADMA Biologics Inc trades at $9.81 (market cap $2.22B), while iShares Core MSCI EAFE ETF trades at $100.75. The key difference: iShares Core MSCI EAFE ETF is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | IEFA | |
|---|---|---|
Market Cap | $2.22B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $20.38 | $101.09 |
52-Week Low | $7.60 | $84.72 |
Enterprise Value | $2.29B | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
IEFA (iShares Core MSCI EAFE ETF) trades at $101.09, up 1.1% with a bullish technical signal from moving averages. The fund provides exposure to developed international markets excluding the US and Canada, with a competitive 0.07% expense ratio and 3.30% dividend yield. Recent news highlights its role in diversification strategies amid S&P 500 concentration concerns.
The outlook remains positive given international diversification benefits and potential Fed rate cut catalysts. Key risks include developed market monetary policy shifts and currency fluctuations. Analyst sentiment favors IEFA for its cost efficiency and income generation, though emerging market alternatives offer different growth profiles.
Trailing returns across standard periods
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →IEFA tracks the MSCI EAFE Investable Market Index, offering broad exposure to large, mid, and small-cap stocks in developed markets across Europe, Australasia, and the Far East. It serves as a low-cost core holding for international diversification, excluding the U.S. and Canada.
Read more on IEFA →